BioSpace News Archive

Tessera Therapeutics today announced advancements across its Gene Writing™ and non-viral delivery platforms including data demonstrating the potential of Gene Writers™ to write therapeutic messages in the genome of non-human primates (NHPs), to generate tumor-clearing chimeric antigen receptor (CAR)-T cells by all-RNA delivery, and the ability to target non-viral delivery systems to hematopoietic stem cells (HSCs) and T cells.

Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced preliminary fourth quarter and full year 2022 revenue and provided a business update.

Eledon Pharmaceuticals, Inc., announced a business update aimed at maximizing shareholder value by prioritizing resources on its ongoing clinical development efforts in kidney transplantation.

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has partnered with Celltrion for the development of RT-111, an orally administered ustekinumab biosimilar.

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced that it has extended the Rostock International Parkinson’s Disease Study to recruit and genetically test additional patients over the next few years.

FSD Pharma Inc. makes several announcements.

Verustat, a full-service remote care management company, today announced promising clinical results showing the ability of Verustat’s Remote Patient Monitoring (RPM) to lower blood pressure.

Athersys, Inc. today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2).

CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary unaudited fourth quarter and full year 2022 revenue results, and provided a 2023 business outlook.

Dunad Therapeutics today announced the appointment of Michael Bonney as Chair of its Board of Directors.